Molecular Weight(MW): 345.42
Omeprazole is a proton pump inhibitor, used to treat dyspepsia, peptic ulcer disease, gastroesophageal reflux disease, laryngopharyngeal reflux, and Zollinger–Ellison syndrome.
Purity & Quality Control
Choose Selective Proton Pump Inhibitors
|Description||Omeprazole is a proton pump inhibitor, used to treat dyspepsia, peptic ulcer disease, gastroesophageal reflux disease, laryngopharyngeal reflux, and Zollinger–Ellison syndrome.|
Omeprazole potently induces cytochrome P4501A1 mRNA expression in primary human hepatocytes, whereas this effect is not detected in mouse primary hepatocytes. Omeprazole induces transcription of reporter genes via the xenobiotic response element that is recognized by the ligand-activated dioxin receptor in human hepatoma cells.  Omeprazole causes a strong inhibition of basal natural killer (NK) activity in spleen cells (SC) from untreated CD2F1 mice. Omeprazole causes a rapid, strong effect on various types of cytotoxic lymphocytes ranging from cytotoxicity inhibition to irreversible cell damage. Omeprazole induces a significant inhibition of cytotoxic activity of all types of effector cells after 30 min incubation.  Omeprazole decreases the activation ofosteoclasts but increases that of osteoblasts in vitro, in part causing an osteopetrosis-like effect. 
|In vivo||Omeprazole blocks H(+)-K(+)-ATPase, thus enhances degeneration and macrophage-mediated elimination of parietal cells and also causes an increase in preparietal cell production. Omeprazole temporarily changes the dynamic features of parietal cells in the rabbit to make them die early and grow fast. |
|In vitro||DMSO||69 mg/mL (199.75 mM)|
|Ethanol||13 mg/mL (37.63 mM)|
|In vivo||Add solvents to the product individually and in order:
2% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT00339768||Completed||Precancerous Gastric Lesions||National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)||May 8, 1995||Phase 3|
|NCT00001191||Completed||Gastrinoma|Zollinger Ellison Syndrome||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC)||February 3, 1983||Phase 2|
|NCT02724150||Not yet recruiting||Gastroduodenal Ulcer|Marginal Ulcer|Peptic Ulcer Hemorrhage||Damascus Hospital||December 2020||Phase 4|
|NCT02892357||Not yet recruiting||Non-erosive Reflux Disease||Xiyuan Hospital of China Academy of Chinese Medical Sciences||January 2017||Phase 2|
|NCT02760615||Not yet recruiting||Colitis, Ulcerative|Crohn Disease||Takeda||January 2017||Phase 4|
|NCT03028103||Not yet recruiting||Diffuse Large B Cell Lymphoma|Primary Mediastinal Lymphoma|Mantle Cell Lymphoma||Epizyme, Inc.||January 2017||Phase 1|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.